Dat	e:2022///	ZZ	
	r Name:Dongli		
Ma	nuscript Title: Efficacy	evaluation of surgery com	bined with chemotherapy for stage IIIA small cell lung cancer
pati	ients: a retrospective analy	sis	
Ma	nuscript number (if known)	:	
In t	he interest of transparency	, we ask you to disclose all	relationships/activities/interests listed below that are
rela	ted to the content of your	manuscript. "Related" mea	ans any relation with for-profit or not-for-profit third
par	ties whose interests may be	e affected by the content o	of the manuscript. Disclosure represents a commitment
to t	ransparency and does not i	necessarily indicate a bias.	If you are in doubt about whether to list a
rela	tionship/activity/interest,	it is preferable that you do	o so.
The	following questions apply	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
maı	nuscript only.		
The	author's relationships/acti	ivities/interests should be	<u>defined broadly</u> . For example, if your manuscript pertains
to t	he epidemiology of hyperte	ension, you should declare	all relationships with manufacturers of antihypertensive
me	dication, even if that medic	ation is not mentioned in	the manuscript.
	•		·
In it	em #1 below, report all sui	pport for the work reporte	ed in this manuscript without time limit. For all other items,
	time frame for disclosure is		,
	time name for disclosure is	s the past so months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
2	Royalties or licenses	X None	

4

Consulting fees

\_X\_\_None

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid			_	
11	Stock or stock options	XNone			
4.2		V N			
12	Receipt of equipment,	XNone		_	
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	X None		_	
13	financial interests	XNone			
	milanolar miler eses			-	
Plea	se summarize the above co	nflict of interest in the foll	owing box:		
_					
N	None.				

Date	e:	_2022/7/22			
You	r Name:	Siming Ji	ang		
				bined with chemotherapy for stage IIIA small cell lung car	ncer
	ents: a retrospect				
	uscript number (i				
	,				
In th	e interest of tran	sparency, v	ve ask you to disclose al	I relationships/activities/interests listed below that are	
				ans any relation with for-profit or not-for-profit third	
		-	_	of the manuscript. Disclosure represents a commitment	
-		-		If you are in doubt about whether to list a	
			s preferable that you do		
	,,	,			
The	following questio	ns apply to	the author's relationshi	ips/activities/interests as they relate to the <u>current</u>	
	uscript only.				
The	author's relations	shins/activi	ties/interests should he	defined broadly. For example, if your manuscript pertains	
		-		all relationships with manufacturers of antihypertensive	
			ion is not mentioned in		
med	ilcation, even ii tii	iat illeuicat	ion is not intentioned in	the manuscript.	
1 !#	#1 h -		- ut f- u thul. u- u- ut	al in this manner of the collection of the first terms.	
				ed in this manuscript without time limit. For all other item	ıs,
tne	time frame for dis	sciosure is t	he past 36 months.		
			Name all entities with	Specifications/Comments	
			whom you have this	(e.g., if payments were made to you or to your	
			relationship or indicate	institution)	
			none (add rows as	,	
			needed)		
			Time frame: Since the initi	ial planning of the work	
1	All support for the	present	X None		
	manuscript (e.g., f	· –	<del></del>		
	provision of study	materials,			
	medical writing, ar	rticle			
	processing charges	s, etc.)			
	No time limit for t	his item.			
			Time frame: pa	st 36 months	
2	Grants or contract	s from	XNone		

any entity (if not indicated

\_X\_\_None

\_X\_\_None

in item #1 above).

Royalties or licenses

Consulting fees

4

			T		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
	Please summarize the above conflict of interest in the following box:				

Date	e:2022/7/2	.2	
You	r <b>Name:</b> Yicher	ng Xiong	
Man	uscript Title: Efficacy of	evaluation of surgery com	hbined with chemotherapy for stage IIIA small cell lung cancer
pati	ents: a retrospective analys	is	
Man	uscript number (if known):		
relat part to tr	ted to the content of your r ies whose interests may be	nanuscript. "Related" me affected by the content o ecessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	following questions apply t uscript only.	o the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	-	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the init	ial planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time forms	at 26 months
2	Grants or contracts from	Time frame: pa	St 56 Months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	X None	

4

Consulting fees

X\_None

			T		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
	Please summarize the above conflict of interest in the following box:				

Date	e:2022/7/2	2	
You	r Name: Mengf	an Qi	
Mar	nuscript Title: Efficacy e	evaluation of surgery com	bined with chemotherapy for stage IIIA small cell lung cancer
pati	ents: a retrospective analys	is	
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your nies whose interests may be	nanuscript. "Related" me affected by the content o ecessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	following questions apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	· · · · · · · · · · · · · · · · · · ·	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4

Consulting fees

X\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ase summarize the above co	nflict of interest in the foll	owing box:
	None.		

Date:	2022/7/2	2		
		Wu		
Manuscript -		valuation of surgery com	bined with chemotherapy for stage IIIA small cell lung car	ncer
Manuscript	number (if known):			
related to th parties whos to transpare	e content of your nose interests may be not	nanuscript. "Related" mea	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
The followin manuscript of		o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to the epide	miology of hyperte	•	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
		port for the work reporte the past 36 months.	d in this manuscript without time limit. For all other item	ıs,
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
1 All supp	ort for the present	X None		
manusci	ript (e.g., funding, n of study materials,			

Time frame: past 36 months

X\_None

X\_None

X\_\_None

medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

3

4

			T		
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
	Please summarize the above conflict of interest in the following box:				

Date: 7/11/2022

Your Name: Alfredo Addeo

Manuscript Title: Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer

patients: a retrospective analysis Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb	Payment to the institution
Royalties or licenses	XNone	
Consulting fees	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Time frame: past  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses  Whom you have this relationship or indicate X_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	Eli-Lilly, AstraZeneca, Amgen	Payment to the institution
	educational events		
6	Payment for expert testimony	Roche, AstraZeneca, Bristol Myers Squibb	Payment to the institution
7	Support for attending meetings and/or travel	Bristol Myers Squibb, AstraZeneca, Amgen	Payment to the institution
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	MSD Oncology, Roche, Takeda, Pfizer, Bristol- Myers Squibb, AstraZeneca, Eli-Lilly	Payment to the institution
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
4.2		V N	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non- financial interests		

### Please summarize the above conflict of interest in the following box:

AA reports advisory board: MSD Oncology, Roche, Takeda, Pfizer, Bristol-Myers Squibb, AstraZeneca, Eli-Lilly; speaker bureau from Eli-Lilly, AstraZeneca, Amgen; research funding from Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb; expert testimony from Roche, AstraZeneca, Bristol Myers Squibb; travels, accommodations, expenses from Bristol Myers Squibb, AstraZeneca, Amgen; outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date	e:July 13th	ı, 2022				
You	r Name:Yoshi	me: Yoshikane Yamauchi				
cano	nuscript Title: Efficacy er patients: a retrospective nuscript number (if known)	e analysis	bined with chemotherapy for stage IIIA small cell lung			
relat part to tr	ted to the content of your i ies whose interests may be	manuscript. "Related" mea e affected by the content of necessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
	following questions apply touscript only.	to the author's relationship	os/activities/interests as they relate to the current			
to th	-	ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.			
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initia	al planning of the work			
1	All support for the present	XNone				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: pas	t 36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
	in item #1 above).					
3	Royalties or licenses	XNone				

4

Consulting fees

X\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
		•	
Plea	ase summarize the above co	onflict of interest in the follo	owing box:
N	lone.		
1 "			

Date:07.18.22					
our Name: Farkhad Manapov					
Manuscript Title: Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell					
ung cancer patients: a retrospective analysis					
Manuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated		Research Institutional Grant from Astrazeneca
	in item #1 above).		
3	Royalties or licenses	None	
_			
4	Consulting fees		AstraZeneca, BrainLab, Elekta

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	None	AstraZeneca, Novartis, Roche, Lilly, BrainLab, Elekta
7	Support for attending meetings and/or travel		AstraZeneca, BrainLab, Elekta
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		AstraZeneca, Novartis
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

### Please summarize the above conflict of interest in the following box:

I received research institutional grant from Astrazeneca; consulting fees and support for attending meetings and/or travel from AstraZeneca, BrainLab, Elekta; honoraria from AstraZeneca, Novartis, Roche, Lilly, BrainLab, Elekta; and I participate on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Novartis.

Please place an "X" next to the following statement to indicate your agreement:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

Manuscript Title:

Manuscript number (if known):

re	ationship/activity/interest,	it is preferable that you o	lo so.
	e following questions apply anuscript only.	to the author's relations	nips/activities/interests as they relate to the current
to me	the epidemiology of hypertedication, even if that medic	ension, you should declar cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.  The manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	st 36 months
3	Royalties or licenses	None	
1	Consulting fees	None	

5	Payment or honoraria for	None	
5	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
1			
7	Support for attending	None	
	meetings and/or travel	0	
	<u> </u>		
8	Patents planned, issued or	None	
	pending	4	
		\ /	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board	<b>\</b>	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	Alama	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	VIVOITE	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

Ø			

Please place an "X" next to the following statement to indicate your agreement:

Date:12.07.2022

Your Name: Jacopo Vannucci

Manuscript Title: Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients:

a retrospective analysis

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

No conflict of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 11/07/2022

Your Name: Alessandro Di Federico

Manuscript Title: Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients:

a retrospective analysis

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	None		
40				
12	Receipt of equipment,	None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	None		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

\_\_\_\_\_

I have no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

Date	2022///2		
	lame: Xiaoxid		
Manus	cript Title: Efficacy e	valuation of surgery com	bined with chemotherapy for stage IIIA small cell lung cance
patien	ts: a retrospective analysi	s	
Manus	cript number (if known):_		
related parties to tran	d to the content of your many be a sparency and does not ne	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
	nship/activity/interest, it llowing questions apply to		ps/activities/interests as they relate to the <u>current</u>
<u>manus</u>	cript only.		
medica In item	ation, even if that medica	tion is not mentioned in to port for the work reporte the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as	all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other items,  Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
4 4		Time frame: Since the initia	al planning of the work
m pi m	Il support for the present anuscript (e.g., funding, rovision of study materials, redical writing, article rocessing charges, etc.) o time limit for this item.	XNone	
		Time frame: pas	st 36 months
aı	rants or contracts from ny entity (if not indicated i item #1 above).	XNone	
	oyalties or licenses	X None	
	- ,		

Consulting fees

X\_None

			T
lectures, pre	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:  None.			

Date	e:2022/7/2	2	
Mar	nuscript Title: Efficacy e	valuation of surgery comb	ined with chemotherapy for stage IIIA small cell lung cancer
-	ents: a retrospective analys nuscript number (if known):		
relate part	ted to the content of your n ies whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	elationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	following questions apply touscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to th	• •	nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.
	em #1 below, report all sup time frame for disclosure is	·	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		

Time frame: past 36 months

X\_None

X\_None

X\_None

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

3

4

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
	_			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
12	services	V Nove		
13	Other financial or non-	XNone		
	financial interests			
DI.			audaa bau.	
riea	ase summarize the above co	innict of interest in the foll	owing box:	
N	lone.			